Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib
Who is this study for? Patients with rheumatoid arthritis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Baricitinib treatment for 12 months 2. Biologics treatment for 12 months 3. Tofacitinib treatment for 12 months
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:
• RA patients
Locations
Other Locations
Japan
Yukio Nakamura
RECRUITING
Matsumoto
Time Frame
Start Date: 2018-11-21
Estimated Completion Date: 2025-11-20
Participants
Target number of participants: 90
Treatments
Active_comparator: BARI
Active_comparator: Bio
Active_comparator: Tofa
Related Therapeutic Areas
Sponsors
Leads: Shinshu University